Results 41 to 50 of about 15,808 (143)

Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms

open access: yesBiofilm
Objectives: New combinations of β-lactams and β-lactamase inhibitors, such as ceftolozane/tazobactam could be useful to combat biofilm-driven chronic infections by extensively resistant (XDR) Pseudomonas aeruginosa but resistance development by mutations
María Fernández-Billón   +9 more
doaj   +1 more source

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

open access: yesBMC Infectious Diseases, 2017
Background A challenge in the empiric treatment of complicated urinary tract infection (cUTI) is identifying the initial appropriate antibiotic therapy (IAAT), which is associated with reduced length of stay and mortality compared with initial ...
Teresa L Kauf   +7 more
doaj   +1 more source

Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates

open access: yesMedicina, 2023
Background: Gram-negative rods are one of the most commonly isolated bacteria within human infections. These microorganisms are typically opportunistic pathogens that pose a serious threat to public health due to the possibility of transmission in the ...
Alicja Sękowska   +2 more
doaj   +1 more source

Pharmacokinetics of ceftolozane-tazobactam during prolonged intermittent renal replacement therapy

open access: yes, 2018
Background: Prolonged intermittent renal replacement therapy (PIRRT) eliminates many drugs, and without dosing data, for new antibiotics like ceftolozane/tazobactam, suboptimal concentrations and treatment failure are likely.
Regli, Adrian   +8 more
core   +1 more source

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

open access: yesCritical Care, 2021
Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites.
Jean-François Timsit   +14 more
doaj   +1 more source

Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination

open access: yes, 2015
Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosage, and administration of ceftolozane/tazobactam, a new antipseudomonal cephalosporin combined with a well ...
Chahine, Elias   +5 more
core   +1 more source

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa

open access: yes, 2022
To evaluate the genotypic and ceftazidime/avibactam-susceptibility profiles amongst ceftolozane/tazobactam-non-susceptible (NS), MBL-negative Pseudomonas aeruginosa in a global surveillance programme.
Gill, Christian M   +3 more
core   +1 more source

A Disproportionality Analysis of β‐lactam Antibiotic Related Blood and Lymphatic System Disorders Based on the FDA Adverse Event Reporting System Database

open access: yesHealth Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims β‐lactam antibiotics stand as the most profoundly impactful classes of antibacterial agents worldwide. Their widespread application has raised safety concerns over adverse events (AEs), such as blood and lymphatic system disorders (BLSDs).
Jing Liu   +6 more
wiley   +1 more source

Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia

open access: yes, 2018
Pseudomonas aeruginosa is a common pathogen causing nosocomial infection. In particular, bloodstream infection (BSI) is associated with a high rate of morbidity and mortality.
Henderson, A.   +7 more
core   +1 more source

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

open access: yesInternational Journal of Infectious Diseases, 2017
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy